



- (51) **International Patent Classification:**
A61K 39/12 (2006.01) *A61P 31/20* (2006.01)
- (21) **International Application Number:**
PCT/US2023/023632
- (22) **International Filing Date:**
25 May 2023 (25.05.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/345,795 25 May 2022 (25.05.2022) US
63/442,109 30 January 2023 (30.01.2023) US
- (71) **Applicant:** BIONTECH SE [DE/DE]; An der Goldgrube 12, 55131 Mainz (DE).
- (72) **Inventors:** PORAN, Asaf; c/o BioNTech US Inc., 40 Erie Street, Suite 110, Cambridge, Massachusetts 02139 (US). ZUANI, Adam; c/o BioNTech US Inc., 40 Erie Street, Suite 110, Cambridge, Massachusetts 02139 (US). DULBERGER, Charles; c/o BioNTech US Inc., 40 Erie Street, Suite 110, Cambridge, Massachusetts 02139 (US). PALOWITCH, Gavin; c/o BioNTech US Inc., 40 Erie Street, Suite 110, Cambridge, Massachusetts 02139 (US).

SROUJI, John; c/o BioNTech US Inc., 40 Erie Street, Suite 110, Cambridge, Massachusetts 02139 (US). DIAO, Huitian; c/o BioNTech US Inc., 40 Erie Street, Suite 110, Cambridge, Massachusetts 02139 (US). ROTHENBERG, Daniel Abram; c/o BioNTech US Inc., 40 Erie Street, Suite 110, Cambridge, Massachusetts 02139 (US). SAHIN, Ugur; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE). DE SILVA, Nilushi S.; c/o BioNTech US Inc., 40 Erie Street, Suite 110, Cambridge, Massachusetts 02139 (US).

- (74) **Agent:** MING-LUM, Andrew N. et al.; CHOATE, HALL & STEWART LLP, Two International Place, Boston, Massachusetts 02110 (US).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

- (54) **Title:** RNA COMPOSITIONS FOR DELIVERY OF MONKEYPOX ANTIGENS AND RELATED METHODS




FIG. 72

- (57) **Abstract:** The present disclosure provides pharmaceutical compositions for delivery of monkeypox antigens (e.g., a monkeypox vaccine) and related technologies (e.g., components thereof and/or methods relating thereto). For example, the present disclosure provides polyribonucleotides encoding one or more monkeypox antigens or fragments thereof.

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*